Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline
Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.
You may also be interested in...
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
With sales of its largest-selling product under threat from generic competition, a couple of new products and cost cuts are put forward to reinvigorate Indivior, a leader in addiction therapies.
Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.